loading
Precedente Chiudi:
$1.11
Aprire:
$1.1
Volume 24 ore:
4.67M
Relative Volume:
2.14
Capitalizzazione di mercato:
$127.20M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.7697
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
+36.32%
1M Prestazione:
+37.87%
6M Prestazione:
-60.00%
1 anno Prestazione:
-73.70%
Intervallo 1D:
Value
$1.10
$1.39
Intervallo di 1 settimana:
Value
$0.9301
$1.39
Portata 52W:
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Nome
Fate Therapeutics Inc
Name
Telefono
858.875.1803
Name
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Dipendente
181
Name
Cinguettio
@fatethx
Name
Prossima data di guadagno
2025-03-05
Name
Ultimi documenti SEC
Name
FATE's Discussions on Twitter

Confronta FATE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.265 127.20M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.75 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.78 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.54 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
230.40 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
228.75 26.16B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-18 Aggiornamento BofA Securities Underperform → Neutral
2024-06-17 Aggiornamento Piper Sandler Neutral → Overweight
2023-03-27 Ripresa Wells Fargo Equal Weight
2023-01-24 Downgrade H.C. Wainwright Buy → Neutral
2023-01-06 Downgrade BMO Capital Markets Outperform → Market Perform
2023-01-06 Downgrade BofA Securities Buy → Underperform
2023-01-06 Downgrade Cowen Outperform → Market Perform
2023-01-06 Downgrade Piper Sandler Overweight → Neutral
2023-01-06 Downgrade Stifel Buy → Hold
2023-01-06 Downgrade Truist Buy → Hold
2023-01-06 Downgrade Wedbush Outperform → Neutral
2023-01-03 Downgrade Guggenheim Buy → Neutral
2022-12-22 Downgrade Oppenheimer Outperform → Perform
2022-12-15 Iniziato Goldman Sell
2022-11-04 Ripresa Cantor Fitzgerald Overweight
2022-10-10 Iniziato Canaccord Genuity Buy
2022-08-18 Ripresa Wells Fargo Overweight
2022-07-28 Iniziato Needham Hold
2022-07-11 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-06-03 Iniziato Robert W. Baird Neutral
2022-02-11 Ripresa BMO Capital Markets Market Perform
2021-12-15 Aggiornamento Wedbush Neutral → Outperform
2021-12-07 Iniziato Cowen Outperform
2021-11-09 Aggiornamento Citigroup Neutral → Buy
2021-08-26 Iniziato Morgan Stanley Equal-Weight
2021-06-07 Aggiornamento H.C. Wainwright Neutral → Buy
2021-05-07 Aggiornamento Wedbush Neutral → Outperform
2021-04-26 Ripresa Jefferies Buy
2021-02-26 Iniziato BofA Securities Buy
2021-02-26 Downgrade Wedbush Outperform → Neutral
2021-02-11 Downgrade Citigroup Buy → Neutral
2021-01-27 Ripresa H.C. Wainwright Neutral
2020-05-13 Iniziato H.C. Wainwright Buy
2020-03-04 Iniziato Barclays Overweight
2020-01-09 Downgrade BMO Capital Markets Outperform → Market Perform
2019-12-30 Reiterato Mizuho Buy
2019-12-09 Aggiornamento Wells Fargo Market Perform → Outperform
2019-11-12 Iniziato SunTrust Buy
2019-11-06 Downgrade Wells Fargo Outperform → Market Perform
2019-10-01 Iniziato Stifel Buy
2019-08-09 Iniziato BTIG Research Buy
2019-07-22 Iniziato Cantor Fitzgerald Overweight
2019-07-12 Iniziato Oppenheimer Outperform
2019-06-13 Iniziato Mizuho Buy
2019-06-07 Iniziato ROTH Capital Neutral
2019-05-31 Iniziato Guggenheim Buy
2019-05-24 Ripresa Citigroup Buy
2019-03-28 Iniziato SVB Leerink Outperform
2019-01-03 Downgrade Stephens Overweight → Equal-Weight
2018-11-05 Iniziato Jefferies Buy
2018-08-01 Iniziato Citigroup Buy
2018-03-06 Downgrade H.C. Wainwright Buy → Neutral
Mostra tutto

Fate Therapeutics Inc Borsa (FATE) Ultime notizie

pulisher
01:01 AM

Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com

01:01 AM
pulisher
11:09 AM

The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com

11:09 AM
pulisher
Apr 19, 2025

Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN

Apr 16, 2025
pulisher
Apr 15, 2025

Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics’ new CAR T-cell therapy fast-tracked by FDA - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics receives RMAT designation from FDA for FT819 - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics gets RMAT status from FDA for lupus treatment - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Buys 12,295 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 14, 2025
pulisher
Apr 09, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc. - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World

Apr 07, 2025
pulisher
Apr 05, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Position Decreased by Thrivent Financial for Lutherans - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Apr 02, 2025
pulisher
Mar 26, 2025

Fate Therap stock hits 52-week low at $0.87 amid sharp decline - Investing.com

Mar 26, 2025
pulisher
Mar 22, 2025

FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst - The AM Reporter

Mar 22, 2025
pulisher
Mar 21, 2025

Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World

Mar 21, 2025
pulisher
Mar 13, 2025

Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN

Mar 13, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

FATE Stock Plummets to 52-Week Low at $0.87 Amidst Sharp Decline - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 08, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance

Mar 08, 2025
pulisher
Mar 08, 2025

Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register

Mar 07, 2025
pulisher
Mar 07, 2025

Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - Nasdaq

Mar 06, 2025

Fate Therapeutics Inc Azioni (FATE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.85
price down icon 0.77%
$71.22
price down icon 2.53%
$32.51
price up icon 0.11%
$24.83
price down icon 0.47%
$97.38
price down icon 1.48%
biotechnology ONC
$231.14
price up icon 0.63%
Capitalizzazione:     |  Volume (24 ore):